INBX
Inhibrx Biosciences Inc.
Company Overview
| Mkt Cap | $1.17B | Price | $92.91 |
| Volume | 342.79K | Change | -0.42% |
| P/E Ratio | -8.3 | Open | $91.51 |
| Revenue | $1.3M | Prev Close | $93.30 |
| Net Income | $-140.1M | 52W Range | $13.97 - $155.29 |
| Div Yield | N/A | Target | $277.50 |
| Overall | 38 | Value | 40 |
| Quality | 44 | Technical | 30 |
No chart data available
About Inhibrx Biosciences Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Latest News
Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | INBX | $92.91 | -0.4% | 342.79K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Inhibrx Biosciences Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW